Qingdao Vland Biotech INC. (SHA:603739)
12.93
-0.22 (-1.67%)
Oct 14, 2026, 11:29 AM CST
SHA:603739 Revenue
Qingdao Vland Biotech INC. had revenue of 364.57M CNY in the quarter ending June 30, 2026, with 6.60% growth. This brings the company's revenue in the last twelve months to 1.42B, up 4.39% year-over-year. In the year 2025, Qingdao Vland Biotech INC. had annual revenue of 1.37B with 3.43% growth. That makes Qingdao Vland Biotech INC. the 16,983rd largest company in the world by revenue and 3,069th in China.
Revenue (ttm)
1.42B
Revenue Growth
+4.39%
P/S Ratio
2.34
Revenue / Employee
935.31K
Employees
1,522
Market Cap
3.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.37B | 45.36M | 3.43% |
| Dec 31, 2024 | 1.32B | 121.86M | 10.16% |
| Dec 31, 2023 | 1.20B | 35.74M | 3.07% |
| Dec 31, 2022 | 1.16B | 12.34M | 1.07% |
| Dec 31, 2021 | 1.15B | 190.57M | 19.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.85B |
| Xiangxue Pharmaceutical | 1.48B |
| Pulike Biological Engineering | 1.02B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Lifecome Biochemistry | 470.43M |
| Guanhao Biotech | 361.40M |
| Jiangsu Bioperfectus Technologies | 310.89M |
| Shanghai Shen Lian Biomedical | 278.46M |